2025 Q4 -tulosraportti
16 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 443 | - | - | ||
| 2 | - | - | ||
| 1 | - | - | ||
| 527 | - | - | ||
| 1 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 618 131 | 3 618 131 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 618 131 | 3 618 131 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 t sitten · MuokattuSee that the discussion is ongoing in the Placera forum. Interesting upcoming news will probably be from New York? Asked AI to search: NYU Langone’s Perlmutter Cancer Center. Integration Status: NYU Langone has officially been listed as an "Early Adopter" site in Immunovia's February 2024 Year-End Report. This means they are currently integrating PancreaSure into their surveillance protocols for high-risk patients (those with familial history or genetic markers like BRCA). Network Reach: This adoption is not limited to Manhattan; it extends across the NYU network into Brooklyn, Queens, and Long Island. Clinical Utility Data: Immunovia is currently gathering "real-world" clinical utility data. Initial survey-based data is expected in Q2 2026. NYU is a key contributor to this dataset, which is the final requirement for the Medicare submission. Regulatory & Financial The approval process in New York is the final piece of the geographical puzzle. The Final 3 States: With California's approval in January 2026, PancreaSure is now available in 47 states. New York is the largest of the remaining three. The "CLEP" Hurdle: New York requires a Clinical Laboratory Evaluation Program (CLEP) permit. Immunovia’s leadership confirmed in late February that they have "made headway" on this specific state permit. Pricing & Access: Even before full NYSDOH licensure for all labs, patients can often access the test if their physician at a center like NYU Langone orders it under specific "clinical utility" research parameters. The $750 discounted cash-pay price remains the standard for those without insurance coverage. Strategic Forecast Table Milestone Expected Timing Current Confidence NYSDOH State Approval April – June 2026 High NYU Langone Full Volume Q2 2026 Medium-High Medicare Submission Mid-2026 High Note on Surveillance: If you or someone you are tracking is looking for immediate access, the Pancreatic Cancer Early Detection Consortium (PRECEDE) at NYU Langone is the primary entry point in the New York area. Would you like me to monitor the Q2 Clinical Utility Data release (expected late May/June) to see the specific success rates reported from the NYU cohort?- ·2 päivää sittenHas this stock also started following the oil price/unrest at the Strait of Hormuz, I wonder? At least the oil price development has calmed down somewhat. They have probably opened Western reserves. So I see that the oil price is hovering around 91 USD now. That's probably fine. How does this affect a biopharma stock, I wonder?
·3 päivää sitten · MuokattuBargain price on the stock!!!,👍 Buying opportunity
·2 päivää sittenThere must be money in the till otherwise they will have to do a reverse split·2 päivää sitten · MuokattuManagement certainly has certain straws in use. But they claimed they had not increased the straw distribution at Q4. So the burn rate was somewhat in the direction of saving operating funds as long as possible. Otherwise, the number of employees (straws) can quickly increase in a process like the one they are currently going through. There is a need for full-time equivalents eventually.- ·3 päivää sittenNow it is world crisis·3 päivää sittenNorway will become even richer·3 päivää sitten · MuokattuNah. Maybe. Now, I'm not a big fan of Jens Stoltenberg. The 'Good day, man, axe handle' man, or his boss Støre (the 'wait and see' man). And the 'saving oneself to ruin' society they aspire to. But he possibly has a point here. Norway earns 400 billion, but simultaneously loses 2000 billion. That said, I now believe that we are a bit better off with the tangible things they deliver in these times of crisis. I have felt that the modern Frp has been a mix of good criticism, but at the same time they cling to populism (one gets used to that, though), but lately there are a couple of issues that have given me total disgust. I also have a distaste for Høyre. Senterpartiet can bury themselves in the field. SV is too red-green. Rødt are "thieves". Krf is not my thing, because I am an atheist. Possibly I scored most for Krf, strangely enough in a self-test. Venstre has simple points I can nod to, but it's not enough for full trust. But I did not vote in this election. Politicians are not to be trusted. Simply said and put. Read: https://www.nrk.no/norge/finansminister-jens-stoltenberg-_ap__-varsler-kutt-i-forkant-av-regjeringens-budsjettkonferanse-1.17800270
- ·6.3.Trump might be somewhat partially constrained by the Iran conflict? https://www.youtube.com/watch?v=g31_u3NZfOg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
16 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sitten · MuokattuSee that the discussion is ongoing in the Placera forum. Interesting upcoming news will probably be from New York? Asked AI to search: NYU Langone’s Perlmutter Cancer Center. Integration Status: NYU Langone has officially been listed as an "Early Adopter" site in Immunovia's February 2024 Year-End Report. This means they are currently integrating PancreaSure into their surveillance protocols for high-risk patients (those with familial history or genetic markers like BRCA). Network Reach: This adoption is not limited to Manhattan; it extends across the NYU network into Brooklyn, Queens, and Long Island. Clinical Utility Data: Immunovia is currently gathering "real-world" clinical utility data. Initial survey-based data is expected in Q2 2026. NYU is a key contributor to this dataset, which is the final requirement for the Medicare submission. Regulatory & Financial The approval process in New York is the final piece of the geographical puzzle. The Final 3 States: With California's approval in January 2026, PancreaSure is now available in 47 states. New York is the largest of the remaining three. The "CLEP" Hurdle: New York requires a Clinical Laboratory Evaluation Program (CLEP) permit. Immunovia’s leadership confirmed in late February that they have "made headway" on this specific state permit. Pricing & Access: Even before full NYSDOH licensure for all labs, patients can often access the test if their physician at a center like NYU Langone orders it under specific "clinical utility" research parameters. The $750 discounted cash-pay price remains the standard for those without insurance coverage. Strategic Forecast Table Milestone Expected Timing Current Confidence NYSDOH State Approval April – June 2026 High NYU Langone Full Volume Q2 2026 Medium-High Medicare Submission Mid-2026 High Note on Surveillance: If you or someone you are tracking is looking for immediate access, the Pancreatic Cancer Early Detection Consortium (PRECEDE) at NYU Langone is the primary entry point in the New York area. Would you like me to monitor the Q2 Clinical Utility Data release (expected late May/June) to see the specific success rates reported from the NYU cohort?
- ·2 päivää sittenHas this stock also started following the oil price/unrest at the Strait of Hormuz, I wonder? At least the oil price development has calmed down somewhat. They have probably opened Western reserves. So I see that the oil price is hovering around 91 USD now. That's probably fine. How does this affect a biopharma stock, I wonder?
- ·3 päivää sitten · MuokattuBargain price on the stock!!!,👍 Buying opportunity·2 päivää sittenThere must be money in the till otherwise they will have to do a reverse split·2 päivää sitten · MuokattuManagement certainly has certain straws in use. But they claimed they had not increased the straw distribution at Q4. So the burn rate was somewhat in the direction of saving operating funds as long as possible. Otherwise, the number of employees (straws) can quickly increase in a process like the one they are currently going through. There is a need for full-time equivalents eventually.
- ·3 päivää sittenNow it is world crisis·3 päivää sittenNorway will become even richer·3 päivää sitten · MuokattuNah. Maybe. Now, I'm not a big fan of Jens Stoltenberg. The 'Good day, man, axe handle' man, or his boss Støre (the 'wait and see' man). And the 'saving oneself to ruin' society they aspire to. But he possibly has a point here. Norway earns 400 billion, but simultaneously loses 2000 billion. That said, I now believe that we are a bit better off with the tangible things they deliver in these times of crisis. I have felt that the modern Frp has been a mix of good criticism, but at the same time they cling to populism (one gets used to that, though), but lately there are a couple of issues that have given me total disgust. I also have a distaste for Høyre. Senterpartiet can bury themselves in the field. SV is too red-green. Rødt are "thieves". Krf is not my thing, because I am an atheist. Possibly I scored most for Krf, strangely enough in a self-test. Venstre has simple points I can nod to, but it's not enough for full trust. But I did not vote in this election. Politicians are not to be trusted. Simply said and put. Read: https://www.nrk.no/norge/finansminister-jens-stoltenberg-_ap__-varsler-kutt-i-forkant-av-regjeringens-budsjettkonferanse-1.17800270
- ·6.3.Trump might be somewhat partially constrained by the Iran conflict? https://www.youtube.com/watch?v=g31_u3NZfOg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 443 | - | - | ||
| 2 | - | - | ||
| 1 | - | - | ||
| 527 | - | - | ||
| 1 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 618 131 | 3 618 131 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 618 131 | 3 618 131 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
16 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sitten · MuokattuSee that the discussion is ongoing in the Placera forum. Interesting upcoming news will probably be from New York? Asked AI to search: NYU Langone’s Perlmutter Cancer Center. Integration Status: NYU Langone has officially been listed as an "Early Adopter" site in Immunovia's February 2024 Year-End Report. This means they are currently integrating PancreaSure into their surveillance protocols for high-risk patients (those with familial history or genetic markers like BRCA). Network Reach: This adoption is not limited to Manhattan; it extends across the NYU network into Brooklyn, Queens, and Long Island. Clinical Utility Data: Immunovia is currently gathering "real-world" clinical utility data. Initial survey-based data is expected in Q2 2026. NYU is a key contributor to this dataset, which is the final requirement for the Medicare submission. Regulatory & Financial The approval process in New York is the final piece of the geographical puzzle. The Final 3 States: With California's approval in January 2026, PancreaSure is now available in 47 states. New York is the largest of the remaining three. The "CLEP" Hurdle: New York requires a Clinical Laboratory Evaluation Program (CLEP) permit. Immunovia’s leadership confirmed in late February that they have "made headway" on this specific state permit. Pricing & Access: Even before full NYSDOH licensure for all labs, patients can often access the test if their physician at a center like NYU Langone orders it under specific "clinical utility" research parameters. The $750 discounted cash-pay price remains the standard for those without insurance coverage. Strategic Forecast Table Milestone Expected Timing Current Confidence NYSDOH State Approval April – June 2026 High NYU Langone Full Volume Q2 2026 Medium-High Medicare Submission Mid-2026 High Note on Surveillance: If you or someone you are tracking is looking for immediate access, the Pancreatic Cancer Early Detection Consortium (PRECEDE) at NYU Langone is the primary entry point in the New York area. Would you like me to monitor the Q2 Clinical Utility Data release (expected late May/June) to see the specific success rates reported from the NYU cohort?
- ·2 päivää sittenHas this stock also started following the oil price/unrest at the Strait of Hormuz, I wonder? At least the oil price development has calmed down somewhat. They have probably opened Western reserves. So I see that the oil price is hovering around 91 USD now. That's probably fine. How does this affect a biopharma stock, I wonder?
- ·3 päivää sitten · MuokattuBargain price on the stock!!!,👍 Buying opportunity·2 päivää sittenThere must be money in the till otherwise they will have to do a reverse split·2 päivää sitten · MuokattuManagement certainly has certain straws in use. But they claimed they had not increased the straw distribution at Q4. So the burn rate was somewhat in the direction of saving operating funds as long as possible. Otherwise, the number of employees (straws) can quickly increase in a process like the one they are currently going through. There is a need for full-time equivalents eventually.
- ·3 päivää sittenNow it is world crisis·3 päivää sittenNorway will become even richer·3 päivää sitten · MuokattuNah. Maybe. Now, I'm not a big fan of Jens Stoltenberg. The 'Good day, man, axe handle' man, or his boss Støre (the 'wait and see' man). And the 'saving oneself to ruin' society they aspire to. But he possibly has a point here. Norway earns 400 billion, but simultaneously loses 2000 billion. That said, I now believe that we are a bit better off with the tangible things they deliver in these times of crisis. I have felt that the modern Frp has been a mix of good criticism, but at the same time they cling to populism (one gets used to that, though), but lately there are a couple of issues that have given me total disgust. I also have a distaste for Høyre. Senterpartiet can bury themselves in the field. SV is too red-green. Rødt are "thieves". Krf is not my thing, because I am an atheist. Possibly I scored most for Krf, strangely enough in a self-test. Venstre has simple points I can nod to, but it's not enough for full trust. But I did not vote in this election. Politicians are not to be trusted. Simply said and put. Read: https://www.nrk.no/norge/finansminister-jens-stoltenberg-_ap__-varsler-kutt-i-forkant-av-regjeringens-budsjettkonferanse-1.17800270
- ·6.3.Trump might be somewhat partially constrained by the Iran conflict? https://www.youtube.com/watch?v=g31_u3NZfOg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 443 | - | - | ||
| 2 | - | - | ||
| 1 | - | - | ||
| 527 | - | - | ||
| 1 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 618 131 | 3 618 131 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 618 131 | 3 618 131 | 0 | 0 |